# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analys...
Wedbush analyst Robert Driscoll reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and maintains $16 price...
HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11...
Wedbush analyst Robert Driscoll reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and maintains $16 price...
Raymond James analyst Laura Prendergast initiates coverage on Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform rati...
Piper Sandler analyst Joseph Catanzaro maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Overweight and maintains $12...